<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119920</url>
  </required_header>
  <id_info>
    <org_study_id>ILUT-401-DED</org_study_id>
    <nct_id>NCT05119920</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream (4%, 6%, 8%)</brief_title>
  <official_title>Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4%, 6%, and 8% BID for the Treatment of Signs and Symptoms of Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2&#xD;
      Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4%, 6%, and&#xD;
      8% BID for the Treatment of Signs and Symptoms of Dry Eye Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in the Eye Dryness Symptom Score of the VAS at Day 28</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Mean change from baseline in the Eye Dryness Symptom Score of the VAS at Day 28.&#xD;
Eye dryness symptom on a Visual Analogue Scale from 0 (no discomfort) to 100 (maximal discomfort)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in Fluorescein Staining of the inferior cornea at Day 28</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Mean change from baseline in Fluorescein Staining of the inferior cornea at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the Eye Dryness Symptom Score of the VAS at the Day 4, 8, and 14 visits</measure>
    <time_frame>Baseline and Days 4, 8, and 14</time_frame>
    <description>Mean change from baseline in the Eye Dryness Symptom Score of the VAS at the Day 4, 8, and 14 visits&#xD;
Eye dryness symptom on a Visual Analogue Scale from 0 (no discomfort) to 100 (maximal discomfort)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Dry Eye Disease</condition>
  <condition>Kerato Conjunctivitis Sicca</condition>
  <arm_group>
    <arm_group_label>Pilocarpine Ophthalmic Topical Cream, 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pilocarpine Ophthalmic Topical Cream, 4%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilocarpine Ophthalmic Topical Cream, 6%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pilocarpine Ophthalmic Topical Cream, 6%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilocarpine Ophthalmic Topical Cream, 8%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pilocarpine Ophthalmic Topical Cream, 8%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilocarpine Ophthalmic Topical Cream, 0%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pilocarpine Ophthalmic Topical Cream, 0%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine Ophthalmic Topical Cream, 4%</intervention_name>
    <description>Pilocarpine Ophthalmic Topical Cream, 4%</description>
    <arm_group_label>Pilocarpine Ophthalmic Topical Cream, 4%</arm_group_label>
    <other_name>Pilocarpine Ophthalmic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine Ophthalmic Topical Cream, 6%</intervention_name>
    <description>Pilocarpine Ophthalmic Topical Cream, 6%</description>
    <arm_group_label>Pilocarpine Ophthalmic Topical Cream, 6%</arm_group_label>
    <other_name>Pilocarpine Ophthalmic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine Ophthalmic Topical Cream, 8%</intervention_name>
    <description>Pilocarpine Ophthalmic Topical Cream, 8%</description>
    <arm_group_label>Pilocarpine Ophthalmic Topical Cream, 8%</arm_group_label>
    <other_name>Pilocarpine Ophthalmic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine Ophthalmic Topical Cream, 0% (placebo)</intervention_name>
    <description>Pilocarpine Ophthalmic Topical Cream, 0% (placebo)</description>
    <arm_group_label>Pilocarpine Ophthalmic Topical Cream, 0%</arm_group_label>
    <other_name>Pilocarpine Ophthalmic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Male or female, 18 years of age or older at the Screening Visit&#xD;
&#xD;
          -  2. Willing and able to provide written informed consent on the IRB/IEC-approved&#xD;
             informed consent form&#xD;
&#xD;
          -  3. Diagnosis of dry eye&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Sensitivity or known allergy to pilocarpine or any of the other excipients of the&#xD;
             formulation&#xD;
&#xD;
          -  2. History of eczema, dermatitis or skin sensitivity to over-the-counter personal care&#xD;
             products such as lotions, creams, makeup, soaps, etc.&#xD;
&#xD;
          -  3. History of, or active iritis or uveitis in either eye&#xD;
&#xD;
          -  4. Pre-existing retinal disease in either eye that may predispose subjects to retinal&#xD;
             detachment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alice Hurtado</last_name>
    <phone>949-367-9600</phone>
    <email>ahurtado@glaukos.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry eye syndromes</keyword>
  <keyword>Eye diseases</keyword>
  <keyword>Corneal diseases</keyword>
  <keyword>Keratoconjunctivitis</keyword>
  <keyword>Pilocarpine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

